Nerisona (Diflucortolone Valerate)

Diflucortolone valerate penetrates skin cells and binds to glucocorticoid receptors inside the nucleus. This receptor complex alters gene transcription, decreasing production of inflammatory cytokines, inhibiting leukocyte migration, and reducing vascular permeability. The overall result is a marked reduction in local inflammation and immune activity.

The specific amount, frequency and duration of Nerisona application are determined by the prescribing healthcare professional based on the severity of the skin condition, the area to be treated, and patient factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for diflucortolone valerate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician.

To request Nerisona, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Diflucortolone valerate is a high‑potency class II topical corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents like hydrocortisone but less potency than class I steroids such as clobetasol. It provides a balance of efficacy and safety for moderate to severe inflammatory dermatoses when used as directed.

Store Nerisona at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight. Do not freeze the preparation, and ensure the container is tightly closed when not in use.

Apply a thin layer of Nerisona to the affected skin area once or twice daily, as instructed by the prescriber. Gently rub the cream or ointment until it disappears. Wash hands before and after application, and avoid contact with eyes, mucous membranes and open wounds unless directed.

Serious risks include skin atrophy, telangiectasia, secondary infections, and systemic corticosteroid effects such as adrenal suppression when used over large areas or for prolonged periods. Patients should report any unusual thinning of the skin, persistent redness, or signs of infection to their healthcare provider promptly.

Nerisona is contraindicated in patients with known hypersensitivity to diflucortolone valerate or any formulation excipients. It should also be avoided on viral, fungal or bacterial skin infections unless combined with appropriate antimicrobial therapy, and in individuals with untreated skin tuberculosis or severe skin atrophy.